Standard breast cancer classification may overlook important differences
This observational study highlights that the current binary classification of breast cancer into estrogen receptor‑positive (ER‑positive) or ER‑negative categories may not adequately reflect the biological continuum and prognostic differences observed across varying levels of estrogen receptor expression.
Accurate sub‑typing of estrogen receptor expression could inform more tailored therapeutic strategies and improve survival outcomes for patients with HER2‑negative breast cancer.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC